nefazodone and Depressive Disorder studies

Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

Research Excerpts

Excerpt	Relevance	Reference
"Fifteen HIV-seropositive patients with DSM-IV major depressive disorder and a 21-item Hamilton Rating Scale for Depression (HAM-D) score of > or =18 were treated with open-label nefazodone for 12 weeks."	9.09	Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. ( Bergam, K; Claypoole, K; Elliott, AJ; Roy-Byrne, PP; Russo, J; Uldall, KK, 1999)
"This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia."	9.08	Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. ( Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA, 1998)
"Nefazodone is a recently marketed compound with demonstrated efficacy in major depression."	9.08	An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996)
" Following on from the suggestion that nefazodone, a specific serotonin reuptake inhibitor and antagonist of 5-HT2, improves 5-HT1A-mediated transmission, we used a pindolol and nefazodone combination treatment for major depressive disorder."	7.69	Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. ( Bakish, D; Hooper, CL; Miller, CA; Thibaudeau, CA; Thornton, MD; Wiens, A, 1997)
" Patients were prescribed nefazodone starting at 50 mg/day, increasing every 4 days until a dosage of 200 mg/day was attained, and subsequently upward to 600 mg/day if no dose-limiting adverse effects appeared."	6.70	Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. ( Arias, F; Carrasco, JL; Díaz-Marsá, M; Huertas, D; Ibañez, A; Martín-Carrasco, M; Moreno, I; Rico-Villademoros, F; Saiz-Ruiz, J, 2002)
"Simvastatin is a hydroxymethyl glutaryl coenzyme A reductase inhibitor commonly used to treat patients with hyperlipidemia."	5.32	Rhabdomyolysis associated with simvastatin-nefazodone therapy. ( Monaghan, MS; Skrabal, MZ; Stading, JA, 2003)
"Nefazodone is a new antidepressant exhibiting properties of selective serotonin reuptake inhibition and serotonin-2 receptor antagonism."	5.29	Probable nefazodone-induced mania in a patient with unreported bipolar disorder. ( Blaisdell, GD; Jermain, DM; Zaphiris, HA, 1996)
"Outpatients with chronic forms of DSM-IV major depressive disorder (N = 681) were randomly assigned to 12 weeks of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combined nefazodone/CBASP."	5.10	Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. ( Arnow, BA; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J, 2002)
"Thus, nefazodone therapy was associated with improvement in mood/anxiety and alcohol use, which seem to be independent of each other in this patient sample."	5.10	Open-label nefazodone in patients with a major depressive episode and alcohol dependence. ( Bobadilla, L; Brown, ES; Dhillon, H; Frol, A; Nejtek, VA; Perantie, D, 2003)
" One hundred fifteen female outpatients who met DSM-IV criteria for major depressive disorder were evaluated before and after 8 weeks of treatment with a selective serotonin reuptake inhibitor, nefazodone, or venlafaxine."	5.10	A comparison of antidepressant response in younger and older women. ( Bagby, RM; Grigoriadis, S; Kennedy, SH, 2003)
"681 patients with chronic major depressive disorder (DSM-IV criteria) participated in a multicenter study of 12 weeks of acute treatment with nefazodone (N = 226), CBASP (N = 228), or the combination (N = 227)."	5.10	Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. ( Borian, FE; Crits-Christoph, P; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J, 2002)
"We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both."	5.09	A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. ( Arnow, B; Dunner, DL; Gelenberg, AJ; Keller, MB; Klein, DN; Markowitz, JC; McCullough, JP; Nemeroff, CB; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J, 2000)
"We describe the successful treatment of five patients with treatment-resistant major depressive disorder (TR-MDD) with a combination pharmacotherapy of pindolol, tryptophan and nefazodone."	5.09	The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder. ( Devarajan, S; Dursun, SM; Kutcher, S, 2001)
"Fifteen HIV-seropositive patients with DSM-IV major depressive disorder and a 21-item Hamilton Rating Scale for Depression (HAM-D) score of > or =18 were treated with open-label nefazodone for 12 weeks."	5.09	Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. ( Bergam, K; Claypoole, K; Elliott, AJ; Roy-Byrne, PP; Russo, J; Uldall, KK, 1999)
"Forty-four outpatients with moderate to severe, nonpsychotic major depressive disorder (DSM-III-R) and insomnia were randomly assigned to receive nefazodone (Days 1-7, 200 mg/day; Days 8-56, 400 mg/day) or fluoxetine (Days 1-56, 20 mg/day)."	5.08	A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. ( Albala, BJ; Erman, MK; Gillin, JC; Rapaport, M; Winokur, A, 1997)
"This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia."	5.08	Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. ( Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA, 1998)
"Nefazodone is a recently marketed compound with demonstrated efficacy in major depression."	5.08	An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996)
"One hundred sixty-six patients suffering from major depressive disorders were treated for 8 weeks with nefazodone in an open study in dosage ranges from 200 to 600 mg."	5.08	Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. ( Case, WG; DeMartinis, N; Garcia España, FG; Greenblatt, DJ; Mandos, LA; Rickels, K; Schweizer, E, 1998)
"This study was an 8-week, randomized, double-blind, parallel-group investigation that compared the effects of nefazodone and fluoxetine on sleep architecture and on clinician- and patient-rated sleep measures in 43 outpatients with moderate to severe, nonpsychotic major depressive disorder and insomnia."	5.08	A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. ( Armitage, R; Cole, D; Rush, AJ; Yonkers, K, 1997)
" This study evaluates the safety and efficacy of nefazodone in patients with major depressive disorder (MDD) in comparison to imipramine and placebo treatments."	5.07	A double-blind comparison of nefazodone, imipramine, and placebo in major depression. ( Ecker, JA; Elie, R; Faludi, G; Fontaine, R; Kaplita, S; Kensler, TT; Ontiveros, A; Roberts, DL, 1994)
"Nefazodone is an antidepressant medication which received approval from the Food and Drug Administration for treatment of major depressive disorder in 1994."	4.80	The antidepressant nefazodone. A review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration. ( Khouzam, HR, 2000)
" Risk of increasing suicidal ideation was higher in subjects taking antidepressants other than paroxetine (odds ratio: 1."	3.77	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. ( Aubry, JM; Bertschy, G; Bondolfi, G; Gex-Fabry, M; Kosel, M; Malafosse, A; Perroud, N; Uher, R, 2011)
"The aim of this study was to estimate the cost effectiveness of nefazodone compared with imipramine or fluoxetine in treating women with major depressive disorder."	3.69	Modelling the cost effectiveness of antidepressant treatment in primary care. ( Anton, SF; Bakish, D; Brown, RE; Feeny, D; Palmer, W; Revicki, DA; Rosser, WW, 1995)
" Following on from the suggestion that nefazodone, a specific serotonin reuptake inhibitor and antagonist of 5-HT2, improves 5-HT1A-mediated transmission, we used a pindolol and nefazodone combination treatment for major depressive disorder."	3.69	Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. ( Bakish, D; Hooper, CL; Miller, CA; Thibaudeau, CA; Thornton, MD; Wiens, A, 1997)
" Patients were prescribed nefazodone starting at 50 mg/day, increasing every 4 days until a dosage of 200 mg/day was attained, and subsequently upward to 600 mg/day if no dose-limiting adverse effects appeared."	2.70	Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. ( Arias, F; Carrasco, JL; Díaz-Marsá, M; Huertas, D; Ibañez, A; Martín-Carrasco, M; Moreno, I; Rico-Villademoros, F; Saiz-Ruiz, J, 2002)
"Continuous and categorical insomnia outcomes, derived from standard clinician- and self-rated assessments, were compared."	2.70	Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. ( Borian, FE; Dunner, DL; Friedman, ES; Keller, MB; Klein, DN; Kornstein, SG; Manber, R; Markowitz, JC; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2002)
"Nefazodone was well tolerated, and no significant changes in sexual function were reported."	2.69	Open trial of nefazodone for combat-related posttraumatic stress disorder. ( Beckham, JC; Davidson, JR; Feldman, ME; Hertzberg, MA; Moore, SD, 1998)
"Nefazodone and placebo treatment were compared in a 6-week trial of 120 patients hospitalized for DSM-III-R diagnosed major depression (without psychosis) at 2 study centers."	2.69	A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. ( Bennett, ME; D'Amico, MF; Feighner, J; Hardy, SA; Kensler, TT; Roberts, DL; Targum, SD, 1998)
" Intensive sampling for pharmacokinetic analyses of NFZ and 3 of its active metabolites was performed after single and multiple dose administration."	2.69	Nefazodone pharmacokinetics in depressed children and adolescents. ( D'Amico, F; Findling, RL; Magnus, RD; Marathe, P; Marcus, RN; Preskorn, SH; Reed, MD, 2000)
"Nefazodone-treated patients had a lower incidence of premature treatment discontinuation and fewer dropouts for adverse events than the imipramine group."	2.68	Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. ( Cohn, CK; Ieni, JR; O'Brien, K; Roberts, DL; Robinson, DS; Schwiderski, UE, 1996)
"Imipramine treatment was not significantly better than placebo for improvement in depression and anxiety ratings in this patient group."	2.68	The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. ( Zajecka, JM, 1996)
"Nefazodone is a new antidepressant drug with pharmacologic effects on both serotonin and norepinephrine neurotransmitters."	2.68	Therapeutic dose range of nefazodone in the treatment of major depression. ( Archibald, DG; Hardy, SA; Marcus, RN; Robinson, DS, 1996)
"Nefazodone is a phenylpiperazine antidepressant with 5-HT2 antagonism and 5-HT reuptake inhibition."	2.67	Nefazodone and imipramine in major depression: a placebo-controlled trial. ( Clary, C; Fox, I; Rickels, K; Schweizer, E; Weise, C, 1994)
"Nefazodone is a selective 5-HT2 receptor antagonist."	2.67	Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. ( Copp, J; D'Amico, MF; Roberts, DL; Robinson, DS; Schwiderski, UE, 1990)
"Nefazodone therapy was also associated with fewer dropouts from adverse effects than was imipramine."	2.66	A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. ( Boyer, WF; D'Amico, MF; Feighner, JP; Fowler, RC; Pambakian, R, 1989)
"Mirtazapine is a potent antagonist of central 2alpha-adrenergic autoreceptors, and heteroreceptors and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors."	2.41	SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. ( Kent, JM, 2000)
"Mirtazapine has minimal inhibitory effects on CYP1A2, CYP3A4, and CYP2D6 in vitro."	2.40	New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. ( Nemeroff, CB; Owen, JR, 1998)
" The mechanism of action of antidepressants allows prediction of both adverse effects and therapeutic effects."	2.40	Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. ( Stahl, SM, 1998)
" Pharmacokinetic and pharmacodynamic changes in this population may predispose patients to experience an increased number of adverse events."	2.40	Pharmacokinetic considerations of antidepressant use in the elderly. ( DeVane, CL; Pollock, BG, 1999)
"Lifetime psychiatric illness is also common in women with PMDD, and although mood disorders predominate, past histories of anxiety disorders are also common, further suggesting an association between PMDD and anxiety disorders."	2.40	Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? ( Yonkers, KA, 1997)
"Nefazodone hydrochloride is a phenylpiperazine antidepressant with a mechanism of action that is distinct from those of other currently available drugs."	2.40	Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. ( Bryson, HM; Davis, R; Whittington, R, 1997)
" The rates for individual side effects with the serotonin selective reuptake inhibitors, nefazodone, and venlafaxine are presented and compared with the adverse event experience for mirtazapine."	2.40	Safety and tolerability of the new antidepressants. ( Nelson, JC, 1997)
"Nefazodone is a new antidepressant drug, chemically unrelated to the tricyclic, tetracyclic or selective serotonin uptake inhibitors."	2.40	Clinical pharmacokinetics of nefazodone. ( Barbhaiya, RH; Greene, DS, 1997)
"Therefore, early relief of insomnia in a depressed patient, in addition to alleviating other symptoms, may increase adherence to treatment and increase daytime performance and overall functioning, while complete relief of insomnia may improve prognosis."	2.40	Antidepressant treatment of the depressed patient with insomnia. ( Thase, ME, 1999)
"Nefazodone does not inhibit rapid-eye movement sleep."	2.39	Nefazodone: a new antidepressant. ( Ellingrod, VL; Perry, PJ, 1995)
"Nefazodone is a unique antidepressant with demonstrated efficacy."	2.39	Tolerability and safety: essentials in antidepressant pharmacotherapy. ( Lader, MH, 1996)
"Nefazodone treatment was associated with fewer side effects than were the control drugs."	2.39	The safety profile of nefazodone. ( Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996)
"Nefazodone-treated patients showed significantly greater improvement in somatic anxiety (HAM-D item 11) ratings than placebo-treated patients from Week 4 through end of treatment (p < or = ."	2.39	Response of anxiety and agitation symptoms during nefazodone treatment of major depression. ( Anton, SF; Fawcett, J; Marcus, RN; O'Brien, K; Schwiderski, U, 1995)
"Nefazodone is a new antidepressant drug with a pharmacologic profile distinct from that of the tricyclic, monoamine oxidase inhibitor, and serotonin selective reuptake inhibitor antidepressants."	2.39	Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. ( Carter, RB; Eison, AS; Mullins, UL; Smith, HL; Taylor, DP; Torrente, JR; Wright, RN; Yocca, FD, 1995)
"Nefazodone is a new antidepressant that combines blockade of the serotonin-2 receptor with serotonin uptake inhibition."	2.39	Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. ( Preskorn, SH, 1995)
"Nefazodone overdose has been reported infrequently."	1.32	Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. ( Hackett, LP; Isbister, GK, 2003)
"Simvastatin is a hydroxymethyl glutaryl coenzyme A reductase inhibitor commonly used to treat patients with hyperlipidemia."	1.32	Rhabdomyolysis associated with simvastatin-nefazodone therapy. ( Monaghan, MS; Skrabal, MZ; Stading, JA, 2003)
"Nefazodone is a relatively potent inhibitor of CYP3A4, a hepatic isoenzyme thought to play a major role in the metabolic elimination of zopiclone."	1.31	Possible interaction of zopiclone and nefazodone. ( Alderman, CP; Condon, JT; Gebauer, MG; Gilbert, AL, 2001)
"To estimate the cumulative incidence of hepatic adverse reactions associated with antidepressants, we used cases of hepatic damage collected via spontaneous reporting and included in the Spanish Pharmacovigilance System database; for exposure, we have used data from drug sales to the Spanish National Health System."	1.31	Hepatotoxicity associated with the new antidepressants. ( Carvajal García-Pando, A; García del Pozo, J; Lucena, MI; Rueda de Castro, AM; Sánchez, AS; Velasco, MA, 2002)
" Appropriate dosing strategies may modulate adverse effects, allowing the patient to move more comfortably toward an efficacious response."	1.31	Antidepressant dosing and switching guidelines: focus on nefazodone. ( Lusk, KM; McEnany, GW; Zajecka, J, 2002)
"The serotonin syndrome is characterized by a constellation of symptoms that include mental status changes, agitation, myoclonus, hyperreflexia, sweating, shivering, tremor, diarrhoea, lack of coordination, and fever."	1.30	Antidepressants and the serotonin syndrome in general practice. ( Dunn, NR; Mackay, FJ; Mann, RD, 1999)
"Nefazodone did not increase rapid-eye-movement (REM) latency and it did not suppress REM sleep."	1.29	The effects of nefazodone on sleep architecture in depression. ( Armitage, R; Cain, J; Roffwarg, HP; Rush, AJ; Trivedi, M, 1994)
"Nefazodone was well tolerated in most patients, with dizziness, joint pain, dry mouth, and sedation as the most commonly reported adverse events."	1.29	An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder. ( Nelson, EC, 1994)
"Nefazodone is a new antidepressant exhibiting properties of selective serotonin reuptake inhibition and serotonin-2 receptor antagonism."	1.29	Probable nefazodone-induced mania in a patient with unreported bipolar disorder. ( Blaisdell, GD; Jermain, DM; Zaphiris, HA, 1996)

Research

Studies (152)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Change in Frontostriatal Reactivity to Reward During MID fMRI Task

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.66)	18.7374
1990's	90 (59.21)	18.2507
2000's	59 (38.82)	29.6817
2010's	2 (1.32)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Argyropoulos, SV	2
Hicks, JA	2
Nash, JR	2
Bell, CJ	2
Rich, AS	2
Nutt, DJ	2
Wilson, S	1
Perroud, N	1
Bondolfi, G	1
Uher, R	1
Gex-Fabry, M	1
Aubry, JM	1
Bertschy, G	2
Malafosse, A	1
Kosel, M	1
Constantino, MJ	1
Laws, HB	1
Arnow, BA	2
Klein, DN	4
Rothbaum, BO	2
Manber, R	5
Saiz-Ruiz, J	1
Ibañez, A	1
Díaz-Marsá, M	1
Arias, F	1
Carrasco, JL	1
Huertas, D	1
Martín-Carrasco, M	1
Moreno, I	1
Rico-Villademoros, F	2
Zajecka, J	5
Dunner, DL	6
Gelenberg, AJ	3
Hirschfeld, RM	2
Kornstein, SG	4
Ninan, PT	3
Rush, AJ	10
Thase, ME	6
Trivedi, MH	7
Borian, FE	4
Keller, MB	8
Thompson, M	1
Samuels, S	1
Ehrentraut, S	1
Rothenhäusler, HB	1
Gerbes, AL	1
Rau, HG	1
Thiel, M	1
Schirren, CA	1
Kapfhammer, HP	1
Nowakowska, E	1
Kus, K	1
Bobkiewicz-Kozłowska, T	1
Grunze, H	1
Marcuse, A	1
Schärer, LO	1
Born, C	1
Walden, J	1
Isbister, GK	1
Hackett, LP	1
Brown, ES	1
Bobadilla, L	1
Nejtek, VA	1
Perantie, D	1
Dhillon, H	1
Frol, A	1
Grigoriadis, S	1
Kennedy, SH	1
Bagby, RM	1
Labbate, LA	1
Croft, HA	1
Oleshansky, MA	1
Skrabal, MZ	1
Stading, JA	1
Monaghan, MS	1
Dremencov, E	1
Gispan-Herman, I	1
Rosenstein, M	1
Mendelman, A	1
Overstreet, DH	1
Zohar, J	1
Yadid, G	1
Hundal, KS	1
Chen, S	1
Moore, W	1
Tranos, P	1
Joshi, N	1
Conway, CR	1
McGuire, JM	1
Baram, VY	1
Lemonde, S	1
Du, L	1
Bakish, D	3
Hrdina, P	1
Albert, PR	1
Carmody, TJ	2
Ibrahim, HM	1
Markowitz, JC	3
Keitner, GI	1
Arnow, B	2
Kocsis, JH	2
Nemeroff, CB	4
Fawcett, J	2
Russell, JM	2
Jody, DN	1
Ciraulo, DA	1
Knapp, C	1
Rotrosen, J	1
Sarid-Segal, O	1
Ciraulo, AM	1
LoCastro, J	1
Greenblatt, DJ	2
Leiderman, D	1
Malani, AK	1
Ammar, H	1
Dubarek, W	1
Kucia, K	1
Goldberg, RJ	2
Kupecz, D	1
Sussman, N	3
Nelson, EC	2
Preskorn, SH	3
Taylor, DP	1
Carter, RB	1
Eison, AS	1
Mullins, UL	1
Smith, HL	1
Torrente, JR	1
Wright, RN	1
Yocca, FD	1
Mendels, J	2
Reimherr, F	1
Marcus, RN	7
Roberts, DL	9
Francis, RJ	1
Anton, SF	4
O'Brien, K	2
Schwiderski, U	1
Rickels, K	4
Robinson, DS	7
Schweizer, E	4
Kensler, TT	4
English, PA	1
Archibald, DG	3
Ansseau, M	1
Darimont, P	1
Lecoq, A	1
De Nayer, A	1
Evrard, JL	1
Krémer, P	1
Devoitille, JM	1
Dierick, M	1
Mertens, C	1
Mesotten, F	1
Clary, C	1
Fox, I	1
Weise, C	1
Armitage, R	3
Trivedi, M	2
Cain, J	1
Roffwarg, HP	1
Fontaine, R	2
Ontiveros, A	1
Elie, R	1
Kaplita, S	1
Ecker, JA	1
Faludi, G	1
Cloninger, CR	2
Sofuoglu, M	1
Debattista, C	1
Zajecka, JM	1
Cohn, CK	1
Schwiderski, UE	3
Ieni, JR	1
Montgomery, SA	2
Smith, JM	1
Stringfellow, JC	1
Kaplita, SB	3
Seminara, JA	1
Lader, MH	1
Baldwin, DS	1
Hawley, CJ	1
Abed, RT	1
Maragakis, BP	1
Cox, J	1
Buckingham, SA	1
Pover, GH	1
Ascher, A	1
Hardy, SA	2
Rothschild, AJ	1
DeMartinis, NA	1
Ketter, TA	1
Callahan, AM	1
Post, R	1
Shammi, C	1
Ghaemi, SN	1
Irizarry, MC	1
Ellingrod, VL	1
Perry, PJ	1
Brown, RE	3
Clark, M	1
Kraus, RP	1
Stoudemire, A	1
Eberstein, S	1
Adler, LA	1
Angrist, B	1
Simpson, JS	1
Micheal, A	1
Ramana, R	1
Pecknold, JC	1
Langer, SF	1
Zaphiris, HA	1
Blaisdell, GD	1
Jermain, DM	1
Gupta, S	1
Gilroy, WR	1
Warnock, JK	1
Biggs, F	1
Livingston, MG	1
Clark, A	1
Revicki, DA	2
Gonzales, J	1
Culpepper, L	1
Hales, RE	2
Reynolds, RD	1
Dubin, H	1
Spier, S	1
Giannandrea, P	1
Davis, R	1
Whittington, R	1
Bryson, HM	1
Möller, HJ	1
Volz, HP	2
Yonkers, KA	2
Yonkers, K	1
Cole, D	1
Gillin, JC	2
Rapaport, M	1
Erman, MK	2
Winokur, A	2
Albala, BJ	2
Benazzi, F	2
Schwartz, K	1
van Laar, MW	1
Hooper, CL	1
Thornton, MD	1
Wiens, A	1
Miller, CA	1
Thibaudeau, CA	1
Frazer, A	1
Nelson, JC	2
Nelson, E	1
Greene, DS	1
Barbhaiya, RH	1
Narayan, M	1
Anderson, G	1
Cellar, J	1
Mallison, RT	1
Price, LH	1
Case, WG	1
DeMartinis, N	1
Mandos, LA	1
Garcia España, FG	1
Owen, JR	1
Feighner, J	1
Targum, SD	1
Bennett, ME	1
D'Amico, MF	3
Moldofsky, H	1
Vogel, GW	1
Fleming, JB	1
Montplaisir, J	1
McQuade, RD	3
Richelson, E	1
Hertzberg, MA	1
Feldman, ME	1
Beckham, JC	1
Moore, SD	1
Davidson, JR	1
Hamilton, SP	1
Klimchak, C	1
Nunes, EV	1
Campo, JV	1
Smith, C	1
Perel, JM	1
Stahl, SM	2
Balon, R	1
Palmer, W	1
Rosser, WW	1
Feeny, D	1
Elliott, AJ	1
Russo, J	1
Bergam, K	1
Claypoole, K	1
Uldall, KK	1
Roy-Byrne, PP	1
Feiger, AD	1
Bielski, RJ	1
Bremner, J	1
Heiser, JF	1
Wilcox, CS	1
Horst, WD	1
Joffe, G	1
Appelberg, B	1
Rimón, R	1
Brodie-Meijer, CC	1
Diemont, WL	1
Buijs, PJ	1
Rajagopalan, M	1
Little, J	1
DeVane, CL	2
Pollock, BG	1
Fava, M	1
Kent, JM	1
Faber, RA	1
Benzick, JM	1
McCullough, JP	1
Scott, J	1
Lerner, V	1
Matar, MA	1
Polyakova, I	1
Mackay, FJ	1
Dunn, NR	2
Mann, RD	2
Mackay, FR	1
Martin, RM	1
Pearce, GL	1
Freemantle, SN	1
Goodnick, PJ	1
Jorge, CA	1
Hunter, T	1
Kumar, AM	1
Findling, RL	1
Magnus, RD	1
D'Amico, F	1
Marathe, P	1
Reed, MD	1
Baty, P	1
Khouzam, HR	1
Rubin, RT	1
Umanoff, DF	1
Duncan, BL	1
Miller, SD	1
Veijola, JM	1
Montejo, AL	1
Llorca, G	1
Izquierdo, JA	1
Ferguson, JM	2
Baker, SM	1
Shrivastava, RK	1
Hartford, JT	1
Borian, F	1
Ieni, J	1
Jody, D	1
Pan, JY	1
Ginsberg, DL	1
Bikoff, J	1
Dursun, SM	1
Devarajan, S	1
Kutcher, S	1
Chelben, J	1
Strous, RD	1
Lustig, M	1
Baruch, Y	1
Roth, L	1
Alderman, CP	1
Gebauer, MG	1
Gilbert, AL	1
Condon, JT	1
Carvajal García-Pando, A	1
García del Pozo, J	1
Sánchez, AS	1
Velasco, MA	1
Rueda de Castro, AM	1
Lucena, MI	1
Grothe, DR	2
Smith, SL	2
Schatzberg, AF	2
Prather, MR	1
Laird, LK	3
Wright, CW	2
Charney, DS	1
Brady, KT	1
Kaltsounis-Puckett, J	1
Bailey, L	1
Seabolt, JL	1
McEnany, GW	1
Lusk, KM	1
Hilty, DM	1
Brunson, GH	1
Crits-Christoph, P	1
Edwards, C	1
Wilson, SJ	1
Friedman, ES	1
Copp, JE	1
Copp, J	1
Feighner, JP	1
Pambakian, R	1
Fowler, RC	1
Boyer, WF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response: A Comparison of Premenopausal, Perimenopausal and Postmenopausal Women[NCT00188396]		44 participants (Actual)	Interventional	2004-04-30	Completed
Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009]	Phase 4	20 participants (Actual)	Interventional	2019-01-02	Completed
Effectiveness of the Bonny Method of Guided Imagery and Music (GIM) in the Treatment of Depression: A Randomized Controlled Trial[NCT03917979]		30 participants (Anticipated)	Interventional	2019-03-20	Recruiting
Efficacy of Nefazodone in Cocaine Dependent Subjects[NCT00015210]	Phase 2	69 participants (Actual)	Interventional	1997-02-28	Completed
Motivational Interviewing to Reduce Substance Use Among Depression Patients[NCT02420561]		307 participants (Actual)	Interventional	2010-10-31	Completed
Cortical rTMS as a Treatment for Depression[NCT05487911]		50 participants (Anticipated)	Interventional	2023-06-14	Enrolling by invitation
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042]		80 participants (Anticipated)	Interventional	2022-01-04	Recruiting
CBASP Augmentation for Treatment of Chronic Depression[NCT00057551]	Phase 4	491 participants (Actual)	Interventional	2003-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks

Depressive Symptoms as Measured by the MASQ-AD

Intervention	percent signal change (Mean)
	Caudate Baseline	Caudate Posttreatment	Nucleus Accumbens Baseline	Nucleus Accumbens Posttreatment	Putamen Baseline	Putamen Posttreatment
Perimenopausal Women, Depressed	.0704	.0475	.0623	.0280	.0399	.0408

The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)

Remission

Intervention	score on a scale (Mean)
	Baseline Week 1	Week 2	Week 3	Post Treatment Week 4
Perimenopausal Women, Depressed	72.1	62.4	57.2	54.5

Hamilton Depression Scale (HAM-D)<8 and does not meet DSM-IV criteria for Major Depressive Disorder for 2 consecutive visits (NCT00057551)
Timeframe: 12 weeks

Intervention	percentage of participants (Number)
CBASP	38.5
Brief SP	31.0
Medication Only	39.5

Article	Year
[Pharmacological justification for the use of new antidepressant drugs]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2002, Volume: 13, Issue:75 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv	2002
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 10 Topics: Antidepressive Agents; Bupropion; Controlled Clinical Trials as Topic; Depressive Disorder; Doxepin;	2003
[Applications and safety of modern antidepressants in patients with liver diseases]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007, Volume: 60, Issue:1-2 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cycloprop	2007
Nefazodone and venlafaxine: two new agents for the treatment of depression. The Journal of family practice, 1995, Volume: 41, Issue:6 Topics: Antidepressive Agents; Consumer Product Safety; Cyclohexanols; Depressive Disorder; Dose-Response Re	1995
New antidepressants. The Nurse practitioner, 1995, Volume: 20, Issue:9 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Fluvoxamine; H	1995
The potential benefits of serotonin receptor-specific agents. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Humans; Isoxazoles; Ondansetron; Piperazines;	1994
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. The Journal of clinical psychiatry, 1995, Volume: 56 Suppl 6 Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressi	1995
Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. The Journal of clinical psychiatry, 1995, Volume: 56 Suppl 6 Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Dose-Response Relationship, D	1995
Response of anxiety and agitation symptoms during nefazodone treatment of major depression. The Journal of clinical psychiatry, 1995, Volume: 56 Suppl 6 Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder; Double-Blind Meth	1995
Evolutionary trends in the pharmacotherapeutic management of depression. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antidepressive Agents; Antidepressive Agents, Tricycl	1994
Efficacy in long-term treatment of depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder;	1996
The safety profile of nefazodone. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agent	1996
Tolerability and safety: essentials in antidepressant pharmacotherapy. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressiv	1996
The diagnosis and treatment of late-life depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 5 Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Di	1996
Nefazodone: a new antidepressant. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1995, Dec-15, Volume: 52, Issue:24 Topics: Animals; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Piperazines; Triazol	1995
New antidepressant drugs and the treatment of depression in the medically ill patient. The Psychiatric clinics of North America, 1996, Volume: 19, Issue:3 Topics: Adjustment Disorders; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive	1996
Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs, 1997, Volume: 53, Issue:4 Topics: Animals; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Piperazines; Triazol	1997
Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs, 1996, Volume: 52, Issue:5 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder;	1996
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 3 Topics: 1-Naphthylamine; Adult; Age of Onset; Anxiety; Anxiety Disorders; Buspirone; Carbon Dioxide; Comorbi	1997
Antidepressants. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 6 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C	1997
Safety and tolerability of the new antidepressants. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 6 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv	1997
Clinical pharmacokinetics of nefazodone. Clinical pharmacokinetics, 1997, Volume: 33, Issue:4 Topics: Adult; Age Factors; Aged; Analgesics; Antidepressive Agents, Second-Generation; Depressive Disorder;	1997
New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depression and anxiety, 1998, Volume: 7 Suppl 1 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrom	1998
Pharmacokinetic interactions of antidepressants. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 10 Topics: Antidepressive Agents; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P	1998
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 18 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Depressive Disord	1998
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Journal of affective disorders, 1998, Volume: 51, Issue:3 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip	1998
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Journal of affective disorders, 1998, Volume: 51, Issue:3 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip	1998
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Journal of affective disorders, 1998, Volume: 51, Issue:3 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip	1998
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Journal of affective disorders, 1998, Volume: 51, Issue:3 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip	1998
Antidepressant treatment of the depressed patient with insomnia. The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 17 Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Human	1999
Care of the sexually active depressed patient. The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 17 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Tria	1999
Pharmacokinetic considerations of antidepressant use in the elderly. The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 20 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Ge	1999
New approaches to the treatment of refractory depression. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 1 Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Drug Therapy, Combination; Humans; Lithium; M	2000
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet (London, England), 2000, Mar-11, Volume: 355, Issue:9207 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder;	2000
New strategies for treating chronic depression. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 11 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Disease; Clinical Trials as	2000
The antidepressant nefazodone. A review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration. Journal of psychosocial nursing and mental health services, 2000, Volume: 38, Issue:8 Topics: Antidepressive Agents, Second-Generation; Biological Availability; Depressive Disorder; Dose-Respons	2000
The effects of antidepressants on sexual functioning in depressed patients: a review. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 3 Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind	2001
Clinical significance of monitoring early symptom change to predict outcome. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 4 Topics: Algorithms; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Mental Disorders; Pip	2001
Acute and maintenance treatment of chronic depression. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 6 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive B	2001
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:4 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Controlled	2001
Pharmacology of antidepressants: focus on nefazodone. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 1 Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Drug Interactions;	2002
Clinical use of nefazodone in major depression: a 6-year perspective. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 1 Topics: Age Factors; Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder; Hospita	2002
Overview of psychiatric disorders and the role of newer antidepressants. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 1 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disor	2002
Six-year perspectives on the safety and tolerability of nefazodone. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 1 Topics: Age Factors; Antidepressive Agents, Second-Generation; Body Weight; Chronic Disease; Depressive Diso	2002
Cost savings with nefazodone in treating depression. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 1 Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cost Savings; Depr	2002

Article	Year
Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. Journal of sleep research, 2009, Volume: 18, Issue:3 Topics: Adult; Affect; Algorithms; Antidepressive Agents, Second-Generation; Delta Rhythm; Depressive Disord	2009
The relation between changes in patients' interpersonal impact messages and outcome in treatment for chronic depression. Journal of consulting and clinical psychology, 2012, Volume: 80, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Ther	2012
Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. CNS drugs, 2002, Volume: 16, Issue:9 Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Piperazin	2002
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Chronic Disease; Cognitive Beha	2002
Nefazodone in psychotic unipolar and bipolar depression: a retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol. Neuropsychobiology, 2002, Volume: 46 Suppl 1 Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; An	2002
Open-label nefazodone in patients with a major depressive episode and alcohol dependence. Progress in neuro-psychopharmacology & biological psychiatry, 2003, Volume: 27, Issue:4 Topics: Adult; Affect; Alcoholism; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; D	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2005, Volume: 30, Issue:2 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi	2005
Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction (Abingdon, England), 2005, Volume: 100 Suppl 1 Topics: Adult; Antidepressive Agents, Second-Generation; Cocaine-Related Disorders; Depressive Disorder; Dia	2005
A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. The Journal of clinical psychiatry, 1995, Volume: 56 Suppl 6 Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Depressive Di	1995
Nefazodone: aspects of efficacy. The Journal of clinical psychiatry, 1995, Volume: 56 Suppl 6 Topics: Ambulatory Care; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Administratio	1995
Long-term treatment of depression with nefazodone. Psychopharmacology bulletin, 1994, Volume: 30, Issue:2 Topics: Antidepressive Agents; Chronic Disease; Depressive Disorder; Double-Blind Method; Humans; Imipramine	1994
Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology, 1994, Volume: 115, Issue:1-2 Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder; Double-Blind Met	1994
Nefazodone and imipramine in major depression: a placebo-controlled trial. The British journal of psychiatry : the journal of mental science, 1994, Volume: 164, Issue:6 Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Me	1994
A double-blind comparison of nefazodone, imipramine, and placebo in major depression. The Journal of clinical psychiatry, 1994, Volume: 55, Issue:6 Topics: Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admini	1994
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Community	1996
Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Drug Admi	1996
Nefazodone in the treatment of severe, melancholic, and recurrent depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder	1996
A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-	1996
Therapeutic dose range of nefazodone in the treatment of major depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Age Factors; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Re	1996
An open-label trial of nefazodone in high comorbidity panic disorder. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depression; Depress	1996
Economic analysis of treating depression with nefazodone v. imipramine. The British journal of psychiatry : the journal of mental science, 1996, Volume: 168, Issue:6 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; D	1996
Curvaceous model of recovery from depression. Lancet (London, England), 1997, Feb-15, Volume: 349, Issue:9050 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi	1997
A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; F	1997
A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:5 Topics: Adult; Affect; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Doubl	1997
Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:2 Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Depress	1998
A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. The Journal of clinical psychiatry, 1998, Volume: 59, Issue:5 Topics: Adult; Age of Onset; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive Diso	1998
Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biological psychiatry, 1998, Jul-01, Volume: 44, Issue:1 Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Circadian Rhythm; Comorbidity; Dep	1998
Open trial of nefazodone for combat-related posttraumatic stress disorder. The Journal of clinical psychiatry, 1998, Volume: 59, Issue:9 Topics: Adult; Ambulatory Care; Anger; Antidepressive Agents, Second-Generation; Combat Disorders; Depressiv	1998
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:4 Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic;	1999
Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. International clinical psychopharmacology, 1999, Volume: 14, Issue:1 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Fem	1999
Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study. International clinical psychopharmacology, 1999, Volume: 14, Issue:4 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disord	1999
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. The New England journal of medicine, 2000, May-18, Volume: 342, Issue:20 Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavi	2000
Nefazodone treatment of adolescent depression: an open-label study of response and biochemistry. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2000, Volume: 12, Issue:2 Topics: Adolescent; Adolescent Behavior; Adolescent Psychiatry; Antidepressive Agents, Second-Generation; De	2000
Nefazodone pharmacokinetics in depressed children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2000, Volume: 39, Issue:8 Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Area Under Curve; Child; C	2000
Does nefazadone alone, the cognitive behavioral-analysis system of psychotherapy, or the combination of both work best for patients with chronic depression? The Journal of family practice, 2000, Volume: 49, Issue:8 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive	2000
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 3 Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Depressive Disorder; Female; Humans	2001
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:1 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Hu	2001
Which depressed patients respond to nefazodone and when? The Journal of clinical psychiatry, 2001, Volume: 62, Issue:3 Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Depressiv	2001
The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder. Journal of psychopharmacology (Oxford, England), 2001, Volume: 15, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Antidepressive Agents; Depressive Disorder; Drug Resistanc	2001
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behav	2002
Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. The British journal of psychiatry : the journal of mental science, 2002, Volume: 180 Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive Disord	2002
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb	2002
Symptom comorbidity in anxiety and depressive disorders. Journal of clinical psychopharmacology, 1990, Volume: 10, Issue:3 Suppl Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method;	1990
Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacology bulletin, 1990, Volume: 26, Issue:1 Topics: Depressive Disorder; Double-Blind Method; Humans; Piperazines; Psychiatric Status Rating Scales; Ran	1990
A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacology bulletin, 1989, Volume: 25, Issue:2 Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Pipe	1989

Article	Year
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics, 2011, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP B	2011
Rhabdomyolysis with simvastatin and nefazodone. The American journal of psychiatry, 2002, Volume: 159, Issue:9 Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Humans; Hype	2002
[Acute liver failure in nefazodone therapy? A case report]. Der Nervenarzt, 2002, Volume: 73, Issue:7 Topics: Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Fatal Outcome; H	2002
Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. Journal of toxicology. Clinical toxicology, 2003, Volume: 41, Issue:2 Topics: Adolescent; Antidepressive Agents, Second-Generation; Antidotes; Biotransformation; Blood Pressure;	2003
Rhabdomyolysis associated with simvastatin-nefazodone therapy. Southern medical journal, 2003, Volume: 96, Issue:10 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Humans; Hydroxymet	2003
The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:1 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generati	2004
Dyskinetopsia during light adaptation associated with nefazodone treatment. Eye (London, England), 2003, Volume: 17, Issue:9 Topics: Adaptation, Ocular; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Ma	2003
Nefazodone-induced liver failure. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:3 Topics: Depressive Disorder; Humans; Liver Failure, Acute; Male; Middle Aged; Piperazines; Triazoles	2004
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. The international journal of neuropsychopharmacology, 2004, Volume: 7, Issue:4 Topics: Adrenergic beta-Antagonists; Adult; Alleles; Antidepressive Agents; Antidepressive Agents, Second-Ge	2004
Medical management of depression. The New England journal of medicine, 2006, Feb-09, Volume: 354, Issue:6 Topics: Chemical and Drug Induced Liver Injury; Depressive Disorder; Duloxetine Hydrochloride; Humans; Liver	2006
An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1994, Volume: 6, Issue:4 Topics: Adult; Antidepressive Agents; Arousal; Comorbidity; Depressive Disorder; Dose-Response Relationship,	1994
Nefazodone for depression. The Medical letter on drugs and therapeutics, 1995, Apr-14, Volume: 37, Issue:946 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Humans; Pip	1995
The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1994, Volume: 10, Issue:2 Topics: Adult; Analysis of Variance; Antidepressive Agents; Depressive Disorder; Electroencephalography; Fem	1994
The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression. Journal of affective disorders, 1995, Oct-09, Volume: 35, Issue:1-2 Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administra	1995
Nefazodone: a novel antidepressant. Psychiatric services (Washington, D.C.), 1995, Volume: 46, Issue:11 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Drug; Dru	1995
Development of obsessive symptoms during nefazodone treatment. The American journal of psychiatry, 1996, Volume: 153, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Dr	1996
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:7 Topics: Alprazolam; Antidepressive Agents, Second-Generation; Anxiety; Cytochrome P-450 Enzyme Inhibitors; D	1996
Antidepressant-induced mania. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1995, Volume: 40, Issue:10 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder; Humans; Male; Middl	1995
Paresthesia as a side effect of the new antidepressant, nefazodone. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1995, Volume: 40, Issue:8 Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Humans; Paresthesia; Piperazines; Triazol	1995
New perspectives in the management of depression. Symposium highlights from ECNP, Venice, September 1995. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:8 Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder; Human	1996
Visual "trails" with nefazodone treatment. The American journal of psychiatry, 1996, Volume: 153, Issue:10 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Dr	1996
Three new antidepressants. Drug and therapeutics bulletin, 1996, Volume: 34, Issue:9 Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depre	1996
Nefazodone and akathisia. Biological psychiatry, 1996, Oct-15, Volume: 40, Issue:8 Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Clonazepam; Depressive Disorder;	1996
Familial akathisia and depression treated with nefazodone. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1996, Volume: 41, Issue:8 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carb	1996
Nefazodone-induced spontaneous ejaculation. The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Ejaculation; Humans; Male; Middle Age	1996
Priapism: trazodone versus nefazodone. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:11 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male; Middle Aged; Piperazine	1996
Probable nefazodone-induced mania in a patient with unreported bipolar disorder. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1996, Volume: 8, Issue:4 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depres	1996
Hair loss associated with nefazodone. The Journal of family practice, 1997, Volume: 44, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Hypotrichosis;	1997
Nefazodone-induced hypoglycemia in a diabetic patient with major depression. The American journal of psychiatry, 1997, Volume: 154, Issue:2 Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Typ	1997
Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:2 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost Savings; Cost-Benefit Analysis; Decisi	1997
Sertraline-induced anorgasmia treated with intermittent nefazodone. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:2 Topics: 1-Naphthylamine; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male;	1997
Nefazodone-induced mania. The American journal of psychiatry, 1997, Volume: 154, Issue:4 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder; Female; Humans; Mid	1997
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy. Journal of psychopharmacology (Oxford, England), 1997, Volume: 11, Issue:2 Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Ther	1997
Nefazodone and visual side effects. The American journal of psychiatry, 1997, Volume: 154, Issue:7 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Middle Aged; Piperazi	1997
Nefazodone. Psychomotor and cognitive effects. Drugs, 1997, Volume: 54, Issue:1 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cognition; Depressive Disorder; Humans; Middl	1997
Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. International clinical psychopharmacology, 1997, Volume: 12, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; D	1997
Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site study. Journal of affective disorders, 1997, Volume: 44, Issue:2-3 Topics: Antidepressive Agents; Depressive Disorder; Female; Humans; Male; Middle Aged; Personality Inventory	1997
[Nefazodone: a new antidepressive agent. Advantages of a dual working principle]. Der Nervenarzt, 1997, Volume: 68, Issue:7 Suppl Ne Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Piperazines; Sleep; Sleep Ini	1997
Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:1 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Carrier Proteins; Depressive	1998
Nefazodone withdrawal symptoms. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1998, Volume: 43, Issue:2 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Male; Phobic Disorders	1998
Treatment of depressed methadone maintenance patients with nefazodone. A case series. The American journal on addictions, 1998,Fall, Volume: 7, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Methadon	1998
Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. Archives of general psychiatry, 1998, Volume: 55, Issue:11 Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Sched	1998
Nefazodone for mood disorder associated with epilepsy. The Journal of clinical psychiatry, 1998, Volume: 59, Issue:12 Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder; Epilepsy; Humans;	1998
Modelling the cost effectiveness of antidepressant treatment in primary care. PharmacoEconomics, 1995, Volume: 8, Issue:6 Topics: Antidepressive Agents; Decision Support Techniques; Depressive Disorder; Female; Fluoxetine; Humans;	1995
Nefazodone-induced clitoral priapism. International clinical psychopharmacology, 1999, Volume: 14, Issue:4 Topics: Antidepressive Agents, Second-Generation; Clitoris; Depressive Disorder; Female; Humans; Middle Aged	1999
Discontinuation symptoms with nefazodone. The Australian and New Zealand journal of psychiatry, 1999, Volume: 33, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Dr	1999
Nafazodone-induced palinopsia. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:2 Topics: Afterimage; Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder; Humans;	2000
Treatment of chronic depression. The New England journal of medicine, 2000, May-18, Volume: 342, Issue:20 Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Chronic Disease; Cognitive Behavioral Th	2000
Nefazodone-associated subjective complaints of burning sensations. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Dr	2000
Antidepressants and the serotonin syndrome in general practice. The British journal of general practice : the journal of the Royal College of General Practitioners, 1999, Volume: 49, Issue:448 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Family Pract	1999
Newer antidepressants: a comparison of tolerability in general practice. The British journal of general practice : the journal of the Royal College of General Practitioners, 1999, Volume: 49, Issue:448 Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Pract	1999
Nefazodone, psychotherapy, and their combination for chronic depression. The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14 Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Controlled Cli	2000
Nefazodone, psychotherapy, and their combination for chronic depression. The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14 Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Controlled Cli	2000
Nefazodone, psychotherapy, and their combination for chronic depression. The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14 Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Dis	2000
Nefazodone, psychotherapy, and their combination for chronic depression. The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14 Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modality Therapy; Depressive Dis	2000
Psychotherapy vindicated? The Harvard mental health letter, 2000, Volume: 17, Issue:6 Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; D	2000
[The antidepressant nefazodone. Healthy sleep fosters compliance]. MMW Fortschritte der Medizin, 2001, May-28, Volume: 143 Suppl 2 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Patient Compliance; Piperazin	2001
Remission of SSRI-induced akathisia after switch to nefazodone. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug	2001
Nefazodone may inhibit the metabolism of carbamazepine: three case reports. European psychiatry : the journal of the Association of European Psychiatrists, 2001, Volume: 16, Issue:5 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Depressive Disorder; Female; Huma	2001
Long-term treatment of recurrent and chronic depression. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 24 Topics: Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Cognitive Behavioral Therapy; Comb	2001
Possible interaction of zopiclone and nefazodone. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:11 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive	2001
Hepatotoxicity associated with the new antidepressants. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:2 Topics: Adult; Aged; Antidepressive Agents; Chemical and Drug Induced Liver Injury; Depressive Disorder; Dru	2002
Antidepressant dosing and switching guidelines: focus on nefazodone. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 1 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Humans;	2002
Novel serotonergic mechanisms and clinical experience with nefazodone. Clinical neuropharmacology, 1992, Volume: 15 Suppl 1 Pt A Topics: Animals; Antidepressive Agents; Depressive Disorder; Humans; Piperazines; Serotonin; Triazoles	1992

nefazodone and Depressive Disorder